CN101102779A - 用于治疗蛋白聚集疾病的含鲨肌醇衍生物的组合物和方法 - Google Patents

用于治疗蛋白聚集疾病的含鲨肌醇衍生物的组合物和方法 Download PDF

Info

Publication number
CN101102779A
CN101102779A CNA2005800467018A CN200580046701A CN101102779A CN 101102779 A CN101102779 A CN 101102779A CN A2005800467018 A CNA2005800467018 A CN A2005800467018A CN 200580046701 A CN200580046701 A CN 200580046701A CN 101102779 A CN101102779 A CN 101102779A
Authority
CN
China
Prior art keywords
disease
chemical compound
amyloid
aforementioned
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800467018A
Other languages
English (en)
Chinese (zh)
Inventor
乔安妮·麦克劳林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN101102779A publication Critical patent/CN101102779A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA2005800467018A 2004-11-17 2005-11-17 用于治疗蛋白聚集疾病的含鲨肌醇衍生物的组合物和方法 Pending CN101102779A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62884004P 2004-11-17 2004-11-17
US60/628,840 2004-11-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2013101874554A Division CN103301094A (zh) 2004-11-17 2005-11-17 用于治疗蛋白聚集疾病的含鲨肌醇衍生物的组合物和方法

Publications (1)

Publication Number Publication Date
CN101102779A true CN101102779A (zh) 2008-01-09

Family

ID=36406797

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2005800467018A Pending CN101102779A (zh) 2004-11-17 2005-11-17 用于治疗蛋白聚集疾病的含鲨肌醇衍生物的组合物和方法
CN2013101874554A Pending CN103301094A (zh) 2004-11-17 2005-11-17 用于治疗蛋白聚集疾病的含鲨肌醇衍生物的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2013101874554A Pending CN103301094A (zh) 2004-11-17 2005-11-17 用于治疗蛋白聚集疾病的含鲨肌醇衍生物的组合物和方法

Country Status (10)

Country Link
US (4) US20080306166A1 (https=)
EP (2) EP1824496A4 (https=)
JP (2) JP2008520589A (https=)
CN (2) CN101102779A (https=)
AU (1) AU2005306531B2 (https=)
BR (1) BRPI0517733A (https=)
CA (1) CA2588423A1 (https=)
MX (1) MX2007005870A (https=)
WO (1) WO2006053428A1 (https=)
ZA (1) ZA200704872B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104974024B (zh) * 2008-03-21 2017-11-14 综合医院公司 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
US8193250B2 (en) 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
WO2007041855A1 (en) * 2005-10-13 2007-04-19 Waratah Pharmaceuticals, Inc. Scyllo-inositol derivatives and their use in the treatment of diseases characterised by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US20070197453A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Compositions and methods for treatment of disorders of protein aggregation
CN103054837A (zh) * 2006-03-09 2013-04-24 瓦拉塔药品公司 用于治疗蛋白积聚病症的环己烷多元醇制剂
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
WO2008061373A1 (en) * 2006-11-24 2008-05-29 Waratah Pharmaceuticals Inc. Combination treatments for alzheimer's disease and similar diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
JP2010523602A (ja) * 2007-04-12 2010-07-15 ワラタ ファーマシューティカルズ， インコーポレイテッド 眼疾患の治療におけるシクロヘキサンヘキソール誘導体の使用
WO2008124930A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
CA2683546A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives in the treatment of .alpha.-synucleinopathies
CA2683580A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Treatment of amyotrophic lateral sclerosis
US20110098309A1 (en) * 2007-07-12 2011-04-28 Acumen Pharmaceuticals, Inc. Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds
US8962677B2 (en) * 2007-07-12 2015-02-24 Acumen Pharmaceuticals, Inc. Methods of restoring cognitive ability using non-peptidic compounds
US9006283B2 (en) * 2007-07-12 2015-04-14 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid β oligomers using non-peptidic compounds
WO2009033151A1 (en) * 2007-09-07 2009-03-12 The Trustees Of Columbia University In The City Of New York Tau protein screening assay
AT506535B1 (de) * 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
ES2521674T3 (es) 2008-09-15 2014-11-13 Transition Therapeutics Ireland Limited Métodos de tratamiento de hiperuricemia y estados patológicos asociados
CA2740124A1 (en) * 2008-10-09 2010-04-15 Waratah Pharmaceuticals Inc. Use of scyllo-inositols for the treatment of macular degeneration-related disorders
US20110081428A1 (en) * 2009-09-16 2011-04-07 The Buck Institute For Age Research Use of thioflavin-like compounds to increase life span and/or health span
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
US20140056901A1 (en) * 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454151A (en) * 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4515722A (en) * 1982-03-30 1985-05-07 Merck & Co., Inc. Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents
US4474806A (en) * 1982-05-10 1984-10-02 Merck & Co., Inc. Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US4952396A (en) * 1986-11-19 1990-08-28 Linus Pauling Institute Of Science & Medicine Method of using phytic acid for inhibiting tumor growth
US4758430A (en) * 1987-01-21 1988-07-19 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
SE8904355D0 (sv) * 1989-12-21 1989-12-21 Perstorp Ab Medicament
US5217959A (en) * 1990-09-06 1993-06-08 Robert Sabin Method of treating multiple sclerosis with phytic acid
US5112814A (en) * 1990-10-24 1992-05-12 Robert Sabin Method of treatment of Parkinson's disease using phytic acid
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
SE9102068L (sv) * 1991-07-03 1993-01-04 Perstorp Ab Derivat av inositol, kompositioner innehaallande dessa samt anvaendning daerav
SE9200547L (sv) * 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
NZ314111A (en) * 1992-10-05 1997-08-22 Virginia Tech Intell Prop Preparation of d-chiro-inositol by reducing d-chiro-3-inosose
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
PT619369E (pt) * 1993-04-05 2003-11-28 Aveve Nv Hidrolise de fitato e composicao enzimatica para a hidrolise de fitato
DE69416594T2 (de) * 1993-08-11 1999-09-23 Hokko Chemical Industry Co. Ltd., Tokio/Tokyo Verfahren zur herstellung von d-chiro inositol
SE502574C2 (sv) * 1994-01-25 1995-11-13 Perstorp Ab En farmaceutisk komposition med förbättrad biotillgänglighet hos inositolfosfat
US5858326A (en) * 1995-06-06 1999-01-12 Neurochem, Inc. Methods of increasing amyloid deposition
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US6232486B1 (en) * 1996-06-11 2001-05-15 Nutrimed Biotech Molecular probes and modulators for PI-PLC and PI 3-kinase
US5977078A (en) * 1996-09-20 1999-11-02 The Regents Of The Univesity Of California Inositol polyphosphate derivatives and methods of using same
US5880099A (en) * 1996-09-20 1999-03-09 The Regents Of The University Of California Inositol polyphosphates and methods of using same
US5998485A (en) * 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
US6153603A (en) * 1997-06-27 2000-11-28 Perstorp Ab Method of treating angiogenesis in tumor tissue
US6331891B1 (en) * 1998-04-07 2001-12-18 Fujitsu Limited Apparatus and method for assembling semiconductor device and semiconductor device thus fabricated
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US6818430B1 (en) * 1999-06-07 2004-11-16 Hokko Chemical Industry Co., Ltd. Process for producing L-epi-2-inosose and novel process for producing epi-inositol
US6329256B1 (en) * 1999-09-24 2001-12-11 Advanced Micro Devices, Inc. Self-aligned damascene gate formation with low gate resistance
EP1221865B1 (en) * 1999-10-18 2007-01-03 Muscletech Research and Development Inc. Food supplement for increasing lean mass and strength
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
DE10031955A1 (de) * 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel
CA2437563C (en) * 2001-02-06 2010-03-23 Qlt Inc. Photodynamic therapy of occult age-related macular degeneration
WO2002062385A2 (en) * 2001-02-06 2002-08-15 Qlt, Inc. Method to prevent vision loss
US20030181531A1 (en) * 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
WO2003007944A1 (en) * 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
EP2298870A1 (en) 2003-10-14 2011-03-23 Hokko Chemical Industry Co., Ltd. Method for producing scyllo-inositol

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104974024B (zh) * 2008-03-21 2017-11-14 综合医院公司 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物

Also Published As

Publication number Publication date
EP1824496A1 (en) 2007-08-29
US20090062403A1 (en) 2009-03-05
JP2008520589A (ja) 2008-06-19
ZA200704872B (en) 2008-12-31
AU2005306531A1 (en) 2006-05-26
CA2588423A1 (en) 2006-05-26
BRPI0517733A (pt) 2008-10-21
EP1824496A4 (en) 2008-07-16
JP2012214516A (ja) 2012-11-08
US20080306166A1 (en) 2008-12-11
US20110201694A1 (en) 2011-08-18
EP2186518A1 (en) 2010-05-19
CN103301094A (zh) 2013-09-18
MX2007005870A (es) 2007-10-10
WO2006053428A1 (en) 2006-05-26
US20060189582A1 (en) 2006-08-24
AU2005306531B2 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
CN101102779A (zh) 用于治疗蛋白聚集疾病的含鲨肌醇衍生物的组合物和方法
Dixit et al. Vitamin C deficiency in the brain impairs cognition, increases amyloid accumulation and deposition, and oxidative stress in APP/PSEN1 and normally aging mice
Forloni et al. Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases
Morroni et al. Early effects of Aβ1-42 oligomers injection in mice: Involvement of PI3K/Akt/GSK3 and MAPK/ERK1/2 pathways
Yang et al. Coenzyme Q10 attenuates β-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation
ES2327521T3 (es) Procedimientos de prevencion, tratamiento y diagnostico de trastornos de la agregacion de proteinas.
AU2013348836B2 (en) Learning and memory improver
US20070197452A1 (en) Treatment of amyloid-related diseases
US20070197453A1 (en) Compositions and methods for treatment of disorders of protein aggregation
Xu et al. Protective effects of icariin on cognitive deficits induced by chronic cerebral hypoperfusion in rats
WO2011106785A2 (en) Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
Ali et al. Evaluation of therapeutic efficacy of vinpocetine in adjuvant induced arthritis model in rats
KR20210005848A (ko) 알츠하이머병을 치료하기 위한 화합물
Kim et al. Anti-amnesic effect of ESP-102 on Aβ1–42-induced memory impairment in mice
Madhi et al. Ginsenoside Re mitigates Aβ1-42-induced neurotoxicity by promoting autophagy and suppressing NLRP3 inflammasome
CA2579188A1 (en) Treatment of amyloid-related diseases
US8871226B2 (en) Methods and compositions for the treatment and diagnosis of cancer
CN101385722A (zh) 预防、治疗和诊断蛋白聚集疾病的方法
CN113924105A (zh) 包含蜂毒提取物作为活性成分的用于预防或治疗神经炎症紊乱的组合物
CN119454685B (zh) 二甲基巯基丙酸的应用
KR20250139876A (ko) 신경퇴행성 질환의 치료를 위한 조성물 및 방법
CN102218055A (zh) 一种治疗阿尔茨海默病的药物
Zhao et al. Ganoderma lucidum spore powder modulates Bcl-2 and Bax expression in the hippocampus and cerebral cortex, and improves learning and memory in pentylenetetrazole-kindled rats**★
Dobson Development of a Cell Culture Model to Investigate Aluminium's Neurotoxicity, and Putative Role in Alzheimer's Disease
Jelic et al. S. 09.04 Memantine: Treatment opportunity for severe dementia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20080109